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Abstract
Background: The use of gadolinium contrast agents in cardiovascular magnetic resonance is well-established
and serves to improve both vascular imaging as well as enable late gadolinium enhancement (LGE) imaging for
tissue characterization. Currently, gadofosveset trisodium, an intravascular contrast agent, combined with a three-
dimensional inversion recovery balanced steady state free precession (3D IR bSSFP) sequence, is commonly used
in pediatric cardiac imaging and yields excellent vascular imaging, but cannot be used for late gadolinium
enhancement. Gadofosveset use remains limited in clinical practice, and manufacture was recently halted, thus an
alternative is needed to allow 3D IR bSSFP and LGE in the same study.
Methods: Here we propose a protocol to give a bolus of 0.1 mL/kg = 0.1 mmol/kg gadobutrol (GADAVIST/
GADOVIST) for time-resolved magnetic resonance angiography (MRA). Subsequently, 0.1 mmol/kg is diluted up to 5
or 7.5 mL with saline and then loaded into intravenous tubing connected to the patient. A 0.5 mL short bolus is
infused, then a slow infusion is given at 0.02 or 0.03 mL/s. Image navigated (iNAV) 3D IR bSSFP imaging is initiated
45–60 s after the initiation of the infusion, with a total image acquisition time of ~5 min. If necessary, LGE imaging
using phase sensitive inversion recovery reconstruction (PSIR) is performed at 10 min after the infusion is initiated.
Results: We have successfully performed the above protocol with good image quality on 10 patients with both
time-resolved MRA and 3D IR bSSFP iNAV imaging. Our initial attempts to use pencil beam respiratory navigation
failed due to signal labeling in the liver by the navigator. We have also performed 2D PSIR LGE successfully, with
both LGE positive and LGE negative results.
Conclusion: A bolus of gadobutrol, followed later by a slow infusion, allows time-resolved MRA, 3D IR bSSFP using
the iNAV navigation technique, and LGE imaging, all in a single study with a single contrast agent.
Keywords: Congenital heart disease, Gadobutrol, Time-resolved magnetic resonance angiography, Steady state
magnetic resonance angiography, Late gadolinium enhancement
* Correspondence: Animesh.Tandon@UTSouthwestern.edu
1Department of Pediatrics, University of Texas Southwestern Medical Center,
5323 Harry Hines Blvd, Dallas 75390, Texas, USA
2Department of Radiology, University of Texas Southwestern Medical Center,
5323 Harry Hines Blvd, Dallas 75390, Texas, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tandon et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:66 
DOI 10.1186/s12968-016-0285-7
Background
Delineation of vascular structures is an especially im-
portant part of cardiovascular magnetic resonance
(CMR) in congenital heart disease (CHD), due to the
frequency of vascular lesions. Current techniques for
vascular imaging in CHD are in three major groups:
 Non-contrast three-dimensional (3D), ECG and
respiratory navigated, T2-prepared, fat saturated
imaging with a balanced steady-state free precession
readout (3D T2-prep bSSFP).
 Contrast-enhanced non-gated conventional or time-
resolved magnetic resonance angiography (MRA).
 And intravascular contrast-enhanced, 3D, ECG and
respiratory navigated, fat saturated imaging with an
inversion recovery pulse and balanced steady-state
free precession readout (3D IR bSSFP) [1, 2].
This latter technique has been shown to be superior to
non-contrast 3D T2-prep bSSFP with both intravascular
and extravascular contrast agents [2], and to IR gradient
recovery echo sequences [3]. The use of image naviga-
tion (iNAV) as opposed to pencil beam navigation fur-
ther improves the image quality [4]. Thus, the standard
of care for imaging at our center was gadofosveset triso-
dium (ABLAVAR, Lantheus Medical Imaging, N. Biller-
ica, MA)-enhanced 3D IR bSSFP imaging. However, due
to gadofosveset trisodium’s albumin binding, the kinetics
are such that they preclude late gadolinium enhance-
ment (LGE) imaging in the same study.
Gadofosveset is approved for use, but there is cur-
rently a disruption in manufacturing (August 1, 2016
(manufacturer communication)). Furthermore, clinical use
of this contrast agent was not ubiquitous. Gadobenate
dimeglumine (MultiHance, Bracco Diagnostic, Milano,
Italy) has been shown to produce similar images as gado-
fosveset [5] given its partial albumin binding characteristics,
but given its linear nature, there are theoretical concerns
regarding a higher risk of central nervous system deposition
[6] and nephrogenic systemic fibrosis (NSF) than with
macrocyclic gadolinium compounds [7]. Gadobutrol
(GADAVIST (Bayer Healthcare Pharmaceuticals, Whip-
pany, NJ) or GADOVIST (Bayer Schering Pharma, Berlin,
Germany)) is a macrocyclic, ionic gadolinium-containing
contrast agent with no known cases of NSF and no
protein-binding characteristics [7], and is FDA-approved in
adult and pediatric patients (including term neonates) to
detect and visualize areas with disrupted blood brain barrier
and/or abnormal vascularity of the central nervous system,
and for use in magnetic resonance angiography (MRA) in
adult and pediatric patients (including term neonates) to
evaluate known or suspected supra-aortic or renal artery
disease [8]. Gadobutrol has shown equal efficacy for LGE
imaging as compared to Gd-DTPA [9].
To address the current disruption of gadofosveset
manufacture, we devised a method of dosing gadobutrol
in order to achieve high-quality 3D IR bSSFP images
while also allowing LGE imaging. Our team was inspired
by Dabir et al. (2012) [10], who performed multi-
dynamic first-pass MRA followed by single-phase T1-
weighted 3D inversion recovery imaging with ECG
triggering and respiratory navigator gating. However,
they used a 3 Tesla MR scanner and a SENSE acceler-
ation factor of 4, while our protocol used a lower SENSE
acceleration factor of 2 at 1.5 Tesla. The novelty of the
current study was the use of image navigated respiratory
motion correction that further accelerated 3D IR bSSFP
image acquisition, since a user-defined scan efficiency
can be chosen prior to the scan [11]. In addition, the in-
jector set up of this protocol allows a slow infusion
protocol using a commonly available injector, without
the need for a separate infusion pump; the use of the in-
jector pump set-up was inspired by Ishida et al. (2011)
[12]. The practicality of this protocol makes it easily ap-
plied in everyday practice.
Methods
Study population
Consecutive patients underdoing contrast-enhanced
CMR with a clinical indication for 3D whole-heart im-
aging at our institution had the protocol performed. We
have IRB approval for retrospective use of clinically-
obtained data, and there is a waiver of consent.
Equipment setup
The CMR studies were performed on an Ingenia 1.5
Tesla scanner (Philips, Best, The Netherlands) with the
32-channel phased array digital receiver coil for signal
reception. The contrast power injector was a Medrad
Spectris Solaris EP (Bayer, Whippany, NJ). The intraven-
ous (IV) tubing used was Mede× 450FL 20 in., APV =
2.4 mL (Smiths Medical ASD Inc., Dublin, OH).
An IV line is placed before the examination for con-
trast administration. Extension tubing is connected be-
tween the end of the injector line and the IV line
connected to the patient (Figs. 1 and 2 explain the over-
all contrast and injector use; Fig. 1a defines extension
tubing set-up); either 2 pieces (if patient was under
50 kg) or 3 pieces (if patient was over 50 kg). This pro-
vides ~5 or 7.5 mL of IV tubing volume between the in-
jector and the patient. A three-way stopcock is attached
between the injector and extension tubing. Both pumps
of the power injector are loaded with saline.
CMR protocol
Initial and gadobutrol bolus time-resolved MRA
Standard bSSFP cine imaging is performed at the begin-
ning of the study (Fig. 3), followed by phase contrast
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imaging. At the time of time-resolved MRA, undiluted
gadobutrol is loaded into the tubing through the stop-
cock (Fig. 1b). At the appropriate time, the injection is
started for time-resolved MRA. The gadobutrol in the
extension tubing is thus injected into the patient. After
time-resolved MRA, contrast-neutral imaging such as
further phase contrast or bSSFP imaging is performed
(Fig. 3).
Gadobutrol slow infusion
When the patient is ready for 3D IR bSSFP iNAV im-
aging, the patient is prepared for gadobutrol slow in-
fusion, as shown in Fig. 2a. In short, diluted
gadobutrol is loaded into the IV extension tubing
through the stopcock. The 3D IR bSSFP iNAV se-
quence is set up to image for approximately 2 to
2.5 min with gating efficiency = 50 % (total imaging
time 4 to 5 min). Field of view and voxel size are
usually manipulated to get the correct imaging time;
representative sequence parameters include repeti-
tion time/echo time (TR/TE) = 3.7/1.86 ms, flip
angle = 70°, field-of-view (FOV) = 320 × 320 × 120 mm,
voxel size = 1.5 × 1.5 × 1.5 mm, k space profile order was
centric (low-high), SENSE factor = 2, inversion time =
220 ms (if run in systole) or 240 ms (if run in diastole)
[4]. This sequence may be run in systole or diastole,
depending on clinical indication, heart rate, and duration
of the quiescent phases in the cardiac cycle [13].
When the 3D IR bSSFP iNAV is ready to run, the con-
tinuous infusion is started, and then after a 45–60 s
delay, the imaging is started, as detailed in Figs. 2b, c,
and 3. The pump rates suggested give about 225–234 s
of injection of the contrast itself, followed by flush. The
imaging sequence time extends beyond the time the
contrast is infusing, but the initial delay between starting
the injection and starting the imaging seems to allow the
gadobutrol to build to a sufficient blood level.
Late gadolinium enhancement imaging
After the 3D IR bSSFP imaging is complete, further
post-contrast imaging can be performed. At 10 to
15 min after the start of the infusion, 2D phase-sensitive
inversion recovery (PSIR) LGE imaging can be per-
formed, if necessary; representative sequence parameters
include repetition time/echo time (TR/TE) = 5.5/6 ms,
flip angle = 25°, echo train length = 22, in-plane reso-
lution = 1.9 × 1.9 mm, slice thickness = 8 mm.
Results
We successfully completed both time-resolved MRA and
3D IR bSSFP iNAV imaging with the above technique
for 10 patients (Fig. 4) with a variety of diagnoses includ-
ing: pulmonary stenosis and sinus venosus atrial septal
Fig. 1 Gadobutrol bolus infusion setup. a Intravenous (IV) extension tubing is connected between the end of the injector line and the IV
connected to the patient; either 2 pieces (if patient is ≤50 kg) or 3 pieces (if patient is >50 kg). This provides 5 or 7.5 mL of IV tubing volume
between the injector and the patient, respectively. A three-way stopcock is attached between the injector and extension tubing. Both pumps of
the power injector are loaded with saline. b When the patient is ready for time-resolved MRA, the technician turns the stopcock off to the in-
jector, and 0.1 mL/kg undiluted gadobutrol is infused into the extension tubing. The power injector is set for pump A to inject 10 mL at 2 mL/s,
and pump B is set to inject 20 mL/s at 2 mL/s. The stopcock is then turned back to allow flow from injector to patient. c Injection is then started
at the appropriate time, and thus the contrast in the tubing is injected into the patient
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defect (ASD) status post surgical intervention (Fig. 4a,
b); hypoplastic right pulmonary artery (RPA) with se-
vere distal RPA stenosis, secundum ASD, coronary
sinus septal defect (Fig. 4c, d); and bicuspid aortic
valve with dilated aortic root (Fig. 4e, f ). The patient
age ranged from 4.7 to 29.4 years (median 11.7 years);
weight ranged from 15.1 to 92.4 kg (median 29.6 kg);
body surface area was 0.64 to 2.02 m2 (median
1.10 m2); heart rate was 60–101 beats per minute
(median 79); and all patients had normal creatinine
for their age (0.3–1.0 mg/dL). Our initial three
attempts used the pencil beam respiratory navigator
with the 3D IR bSSFP sequence; however, all of these
proved to be unusable. This is likely due to artifact
generated by the navigator restore pulse labeling
blood as has been described previously [14]. This
likely caused a compression of the dynamic range and
thus the overall image quality was degraded (Fig. 5).
We have also run 2D PSIR LGE sequences as de-
scribed above, with both positive and negative results
(Fig. 6). Image quality for LGE was excellent in these
cases.
Fig. 2 Gadobutrol slow infusion setup. a Gadobutrol 0.1 mL/kg is diluted with saline to 5 (≤50 kg patient) or 7.5 mL (>50 kg patient). b When
ready for 3D IR bSSFP iNAV imaging, the dilute gadobutrol is loaded into the extension tubing. The 3D IR bSSFP iNAV sequence is set up to
image for approximately 4 to 5 total minutes. c Injector pump A is set to inject 0.5 mL at 2 mL/s, to overcome dead space/saline in the extension
tubing. Injector pump B is set to inject 20 mL at 0.02 mL/s (≤50 kg patient) or 0.03 mL/s (>50 kg patient). The injection is started, and after a
delay of 45–60 s, 3D IR bSSFP iNAV imaging is started
Fig. 3 Example study timeline. This diagram graphically depicts the timeline of an example study using the gadobutrol bolus and slow
infusion protocol
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Conclusion
Given the importance of time-resolved MRA, steady
state 3D IR bSSFP, and LGE in fully evaluating patients
with congenital heart disease, our protocol represents a
step forward in being able to acquire all of these datasets
in a single exam with a single contrast agent. The indi-
vidual features of this protocol are not novel. The slow
infusion, image navigator, bolus technique and late gado-
linium enhancement techniques have been described
[10–12]. The purpose of the protocol is to provide prac-
tical guidance on how to combine these techniques to
enable acquisition of these datasets using existing
injector equipment at 1.5 Tesla magnet field strength.
Our choice of inversion time was influenced by our pre-
vious clinical experience, and by previous work suggest-
ing 280 ms for gadobutrol by Dabir et al. (2012) [10].
However, unlike that study, our contrast agent could not
be completely injected as a slow infusion, because a
bolus injection is required for first-pass MRA. This, in
turn, results in a broader variation of contrast agent
concentration in the blood and so benefits from a
shorter inversion time. In addition, our goal was not to
completely null the myocardium, as might be desired for
coronary imaging, but to have some myocardial
Fig. 4 Time-resolved MRA and 3D IR bSSFP iNAV example images. MRA and 3D IR bSSFP iNAV images, respectively, from (a, b) patient
with pulmonary stenosis and sinus venosus atrial septal defect (ASD) status post surgical intervention; (c, d) patient with hypoplastic right
pulmonary artery (RPA) with severe distal RPA stenosis, secundum ASD, coronary sinus septal defect; (e, f) patient with bicuspid aortic
valve with dilated aortic root
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visualization to allow better identification of the anat-
omy in patients with congenital heart disease. We add-
itionally confirmed our initial choice of 240 ms by
running a Look-Locker immediately after the infusion.
We used 220 ms for systole due to the practical need for
a shorter inversion time at higher heart rates to allow
systolic imaging. This protocol should be further evalu-
ated in prospective studies to ensure that the image
quality of all three image types are comparable to
current standards, and to further optimize imaging pa-
rameters such as inversion time, image acquisition
length compared to infusion duration, and other factors,
but our subjective experience is that it delivers compar-
able images to gadofosveset trisodium-based 3D IR
bSSFP while allowing the added advantage of LGE im-
aging. One potential alternative for centers that do not
have access to image-based navigation techniques may
be to use pencil beam navigation with a higher flip angle
and the navigator restore pulse turned off. However,
given that this reduces the effectiveness of navigation on
the Philips platform, we did not evaluate this option. In
addition, pencil-beam navigation with 3D IR GRE se-
quences on Siemens uses a different implementation of
pulse sequences that does not require the navigator re-
store pulse. We would surmise, therefore, that these
scanners can continue to use the conventional pencil-
beam navigator without incurring the labeling artifact
described above. Our correspondence with pediatric
centers employing Siemens hardware supports this as-
sumption (T. Slesnick, personal communication). Given
the current disruption in gadofosveset trisodium produc-
tion, the importance of this alternative protocol will be
evident to CMR practitioners who care for patients with
congenital heart disease.
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Fig. 6 Example phase sensitive inversion recovery late gadolinium
enhancement images. a, b LGE negative short axis (a) and 4
chamber (b) images from previously mentioned patient with
pulmonary stenosis and sinus venosus atrial septal defect (ASD)
status post surgical intervention. c, d A small area of full-thickness
LGE (yellow arrows) in the mid inferoseptal segment correlating to
the RCA distribution is shown in short axis (a) and 4 chamber (b)
images from a patient with d-transposition of the great arteries,
ventricular septal defect (VSD), and pulmonary stenosis status post
aortic root translocation and VSD closure, and known previous right
coronary kinking status post reimplantation
Fig. 5 Example images of 3D IR bSSFP imaging using pencil beam navigation. As can be seen in all three panels, these proved to be unusable
because the navigator labeled the blood in the liver and thus the overall image quality was degraded. This is perhaps due to the high signal in
the liver causing an overall compression of the dynamic range. a Image from a patient with d-transposition of the great arteries, ventricular septal
defect (VSD), and pulmonary stenosis status post aortic root translocation and VSD closure. b Image from a patient with a large secundum atrial
septal defect. c Image from a patient with trisomy 21 and common AV canal status post surgical repair
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